“In order to achieve that opportunity, we are building new facilities that will be coming online from 2023, 2024 and 2025.”

In context

“then maybe just help us think through what is the supply-demand mismatch right now? Some of your prior comments suggested that there may not be such, but I know you said supply has been an issue over the past sort of couple of years. So would love to get to expanded thoughts there. Caroline Litchfield: Thank you for the question. This is Caroline. So let me start first with the supply, demand. There is significant demand for GARDASIL. This cancer-preventing vaccine in the HPV area has only reached today 9% of the global eligible population. So, there is significant runway ahead of us to protect lives and to drive growth for Merck. Indeed, we've stated that we expect the revenue in year 2030 to be double the $5.7 billion we achieved in 2021. So, we have significant opportunity ahead of us. In order to achieve that opportunity, we are building new facilities that will be coming online from 2023, 2024 and 2025. So we're going to have a step-up in the level of supply to the market that will happen over that period. Specific then to this year, we will see a continuation of the supply into the market as we did in 2021, albeit not quite at the same step-up that we achieved in 2021. So, we remain really confident in our ability to drive strong growth for GARDASIL both in 2022 and the years to come. Peter Dannenbaum: Great. Thanks, Colin. Rob? Rob Davis: Well, just let me say thank you for your time and your interest today. And I'd just like to conclude by again thanking the Merck team globally for their focus and commitment and really in driving the results you've heard about today, but continuing to ensure when we keep the purpose of the Company front and center, which is to deliver for patients. Ho”